# CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

> **NCT06470841** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Navy General Hospital, Beijing** · enrollment: 85 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CHG Combined With Venetoclax and Azacytidine

## Key facts

- **NCT ID:** NCT06470841
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06470841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06470841, "CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06470841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*